Malignant Soft Tissue Neoplasm of Uncertain Differentiation

Malignant Soft Tissue Neoplasm of Uncertain Differentiation — Trials · CancerIndex

Clinical trials

Registered studies

186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 66
Recruiting: 40
Ph III recruiting: 2
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 42.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (29)

clinicaltrialsPublishedShowing 1–50 of 70 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04616560	Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor	recruiting	Phase 2	55	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT07174427	Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma	recruiting	Phase 3	5	Takara Bio Inc.INDUSTRY	1	Sep 28, 2026	clinicaltrials